# Iteration Run Report — 2026-07-05 (Sunday)

**Agent:** diabetes-research-iterate (autonomous scheduled run)
**Papers:** 285 total — 272 VETTED / 13 FLAGGED / 0 unvetted (backlog stays clear)
**Weekly PubMed sweep:** skipped (not Monday)

## Work queue items completed

### 1. Credibility sweep (every run) — CLEAN
- Fabricated PMIDs (>42,000,000): **0**
- "zero SAE / zero rejection" claims: **0**
- "curative / achieves" hits: 3, all benign (TTP399 tissue selectivity; LADA diagnostic cost-effectiveness phrasing; microbiome macro-AUC) + 2 inside the `verify_before_deploy.py` detector itself.

### 2. Gap #10 audit (SILVER, promotion_candidate) — early, due 07-07 → retained SILVER
LADA prevalence *by healthcare setting*. Web search found **no** 2026 setting-segmented SR/MA comparing primary-care vs specialist-clinic prevalence. The 2023 worldwide SR&MA (pooled 8.9%, 95% CI 7.5–10.4, k=51,725) remains the strongest evidence; the LADA primary-care clinical-risk-score protocol study develops PHC screening but reports no setting-stratified prevalence differential. SILVER→GOLD promotion still **not** justified; `promotion_candidate` stays true. Next audit **2026-08-05**.

### 3. Gap #8 audit (SILVER) — early, due 07-07 → retained SILVER
LADA-specific immunomodulator RCT. Evidence base is still the Linköping GAD-Alum + oral vitamin D intralymphatic **pilot** (n=14 GADA+, feasibility/safety only, no primary RCT readout). DIAGNODE-2 and DIAGNODE-B are T1D-only (efficacy limited to HLA DR3-DQ2), which per protocol does not generalize to LADA. No LADA-specific RCT readout in the past 30 days. Next audit **2026-08-05**.

### 4. Path validation — empagliflozin → inflammation (stalest PARTIALLY, last 2026-03-20)
Class-level anti-inflammatory signal **confirmed** by a new SGLT2i IL-6 meta-analysis (18 RCTs, n=5,311). **But** the effect is population-dependent: dapagliflozin > empagliflozin for IL-6 lowering, and EMPIRE-HF showed no hs-CRP effect in heart-failure patients (strongest signal in T2D+CAD, e.g. EMPA-CARD). Kept **PARTIALLY_VALIDATED** (not promoted to full); +2 external PMIDs added. An empagliflozin+colchicine post-STEMI systematic review was noted as relevant to the hub's SGLT2i + anti-inflammatory combination theme.

### 5. Pipeline rebuild — all 41 stages [OK]
`run_quality_improvements.py` completed cleanly, including PMID verification against the PubMed API.

## State
Backup written (`agent_state.json.bak_2026-07-05`). Run recorded (82 total). Queue reprioritized: Gap #10/#8 audit dates advanced to 2026-08-05; verapamil→T1D queued as next-stalest path for the next run.

## Constraint note
Git **push remains blocked** — no GitHub auth in the sandbox (`could not read Username for https://github.com`). Local commit only. **User action required:** `cd Diabetes_Research; git push`.
